We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Infectex announced that it had found positive results from its latest Phase 2b-3 clinical trial of its drug for multidrug-resistant pulmonary tuberculosis.